首页> 美国卫生研究院文献>In Vivo >The Economic Burden of Postoperative Complications Predicted by the Comprehensive Complication Index® in Patients Undergoing Elective Major Hepatopancreaticobiliary Surgery for Malignancy – A Prospective Cost Analysis
【2h】

The Economic Burden of Postoperative Complications Predicted by the Comprehensive Complication Index® in Patients Undergoing Elective Major Hepatopancreaticobiliary Surgery for Malignancy – A Prospective Cost Analysis

机译:术后并发症术后并发症术后并发症的经济负担在接受选修主要肝癌患者对恶性肿瘤的患者中 - 一种预期成本分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background/Aim: Postoperative complications have a tremendous impact on in-hospital costs. The novel Comprehensive Complication Index® (CCI®) summarizes all complications together and is more sensitive than existing morbidity endpoints. The purpose of this study was to assess the correlation of CCI® with in-hospital costs and externally validate a novel cost prediction calculator. Patients and Methods: This was a prospective study including consecutive patients undergoing elective major hepatopancreaticobiliary (HPB) surgery for malignancy at a London tertiary referral hospital. A priori sample size and post-hoc power calculations were performed. Results: Thirty patients were included in the analysis, 14 were female, and the median age was 67 [interquartile range (IQR)=54-74] years. The median Charlson Comorbidity Index was 6 (IQR=5-8). Eighteen patients underwent liver, 9 pancreatic surgery and three a palliative bypass; 11 patients had a major complication (≥grade 3a) according to the Clavien–Dindo classification. The median CCI® was 30.2 (IQR=12.18-39.5). The mean cost per case was 13,908 (SD=4,600) GBP. There was no correlation between the Charlson Comorbidity Index or age with actual cost. However, there was very good correlation of actual cost with the CCI® (r=0.77, 95% confidence interval=0.57-0.89, p<0.001) as well as with the predicted cost (Clavien Cost Prediction Calculator) (r=0.70, 95% confidence interval=0.44-0.85, p<0.001). Conclusion: These findings support the hypothesis that complications are the most important predictor of overall cost in the setting of elective major HPB surgery for malignancy. Furthermore, CCI® and the novel Cost Prediction Calculator can be used in this setting to accurately predict costs using no additional resources.
机译:背景/目的:术后并发症对住院费用产生巨大的影响。新颖的综合并发症指数®(CCI®)总结了所有并发症在一起,比现有的发病率终点更敏感。本研究的目的是评估CCI®的相关与住院成本和外部验证新颖成本预测计算器。患者和方法:这是一项前瞻性研究,包括在伦敦的三级转诊医院接受恶性肿瘤择期hepatopancreaticobiliary(HPB)手术例患者。进行先验样本大小和事后功率计算。结果:30名患者包括在分析中,14为女性,平均年龄为67 [四分位数间距(IQR)= 54-74]年。平均查尔森合并症指数为6(IQR = 5-8)。 18例患者进行了肝,胰9手术和三个姑息旁路; 11例患者根据Clavien-Dindo分类产生了重大并发症(≥grade3A)。平均CCI®为30.2(IQR = 12.18-39.5)。每情况下,平均成本为13908(SD = 4600)GBP。有与实际成本的查尔森合并症指数和年龄之间没有相关性。然而,有一个与CCI®(R = 0.77,95%置信区间= 0.57-0.89,P <0.001),以及与所预测的成本实际成本的很好的相关性(Clavien成本预测计算器)(R = 0.70, 95%置信区间= 0.44-0.85,p <0.001)。结论:这些研究结果支持这一假设并发症是择期手术HPB恶性肿瘤的设置总成本的最重要的预测。此外,CCI®和新的费用预测计算器可以在此设置中使用准确预测不使用额外的资源成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号